Atricure Inc (ATRC)

$32.98

-1.82

(-5.23%)▲

Market is closed - opens 8 PM, 07 Dec 2023

Insights on Atricure Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 100.91M → 98.29M (in $), with an average decrease of 2.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -5.11M → -9.05M (in $), with an average decrease of 76.9% per quarter

  • Vs WST

    In the last 1 year, West Pharmaceutical Services Inc has given 46.2% return, outperforming this stock by 64.0%

  • Vs WST

    In the last 3 years, West Pharmaceutical Services Inc has given 26.5% return, outperforming this stock by 51.0%

Performance

  • $32.91
    $35.08
    $32.98
    downward going graph

    0.23%

    Downside

    Day's Volatility :6.2%

    Upside

    5.99%

    downward going graph
  • $32.27
    $59.61
    $32.98
    downward going graph

    2.15%

    Downside

    52 Weeks Volatility :45.86%

    Upside

    44.67%

    downward going graph

Returns

PeriodAtricure IncSector (Health Care)Index (Russel 2000)
3 Months
-22.41%
0.3%
0.0%
6 Months
-28.08%
1.7%
0.0%
1 Year
-17.83%
-4.0%
-2.4%
3 Years
-23.26%
17.2%
-6.5%

Highlights

Market Capitalization
2.0B
Book Value
$9.77
Dividend Share
0.0
Dividend Yield
6.21%
Earnings Per Share (EPS)
-0.54
PEG Ratio
-1.18
Wall Street Target Price
55.0
Profit Margin
-6.52%
Operating Margin TTM
-8.23%
Return On Assets TTM
-2.34%
Return On Equity TTM
-5.44%
Revenue TTM
380.7M
Revenue Per Share TTM
8.24
Quarterly Revenue Growth YOY
18.099999999999998%
Gross Profit TTM
245.9M
EBITDA
-8.6M
Diluted Eps TTM
-0.54
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.74
EPS Estimate Next Year
-0.7
EPS Estimate Current Quarter
-0.31
EPS Estimate Next Quarter
-0.28

Analyst Recommendation

Buy
    86%Buy
    13%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Atricure Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
12
11
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 66.77%

Current $32.98
Target $55.00

Company Financials

FY17Y/Y Change
Revenue
174.7M
↑ 12.64%
Net Income
-26.9M
↓ 19.34%
Net Profit Margin
-15.39%
↑ 6.1%
FY18Y/Y Change
Revenue
201.6M
↑ 15.4%
Net Income
-21.1M
↓ 21.4%
Net Profit Margin
-10.48%
↑ 4.91%
FY19Y/Y Change
Revenue
230.8M
↑ 14.47%
Net Income
-35.2M
↑ 66.5%
Net Profit Margin
-15.25%
↓ 4.77%
FY20Y/Y Change
Revenue
206.5M
↓ 10.52%
Net Income
-48.2M
↑ 36.83%
Net Profit Margin
-23.32%
↓ 8.07%
FY21Y/Y Change
Revenue
274.3M
↑ 32.83%
Net Income
50.2M
↓ 204.24%
Net Profit Margin
18.3%
↑ 41.62%
FY22Y/Y Change
Revenue
330.4M
↑ 20.43%
Net Income
-46.5M
↓ 192.56%
Net Profit Margin
-14.06%
↓ 32.36%
Q2 FY22Q/Q Change
Revenue
84.5M
↑ 13.35%
Net Income
-14.8M
↓ 2.25%
Net Profit Margin
-17.56%
↑ 2.8%
Q3 FY22Q/Q Change
Revenue
83.2M
↓ 1.52%
Net Income
-12.3M
↓ 17.31%
Net Profit Margin
-14.74%
↑ 2.82%
Q4 FY22Q/Q Change
Revenue
88.0M
↑ 5.74%
Net Income
-4.2M
↓ 66.02%
Net Profit Margin
-4.74%
↑ 10.0%
Q1 FY23Q/Q Change
Revenue
93.5M
↑ 6.21%
Net Income
-6.5M
↑ 55.3%
Net Profit Margin
-6.93%
↓ 2.19%
Q2 FY23Q/Q Change
Revenue
100.9M
↑ 7.94%
Net Income
-5.1M
↓ 20.97%
Net Profit Margin
-5.07%
↑ 1.86%
Q3 FY23Q/Q Change
Revenue
98.3M
↓ 2.6%
Net Income
-9.1M
↑ 76.92%
Net Profit Margin
-9.21%
↓ 4.14%
FY17Y/Y Change
Total Assets
267.7M
↓ 3.15%
Total Liabilities
106.5M
↓ 1.33%
FY18Y/Y Change
Total Assets
356.8M
↑ 33.27%
Total Liabilities
107.4M
↑ 0.79%
FY19Y/Y Change
Total Assets
557.9M
↑ 56.37%
Total Liabilities
310.5M
↑ 189.2%
FY20Y/Y Change
Total Assets
714.5M
↑ 28.08%
Total Liabilities
302.1M
↓ 2.7%
FY21Y/Y Change
Total Assets
615.3M
↓ 13.89%
Total Liabilities
131.6M
↓ 56.46%
FY22Y/Y Change
Total Assets
585.4M
↓ 4.85%
Total Liabilities
128.7M
↓ 2.18%
Q2 FY22Q/Q Change
Total Assets
587.4M
↑ 0.41%
Total Liabilities
130.7M
↑ 6.98%
Q3 FY22Q/Q Change
Total Assets
581.9M
↓ 0.93%
Total Liabilities
131.6M
↑ 0.71%
Q4 FY22Q/Q Change
Total Assets
585.4M
↑ 0.61%
Total Liabilities
128.7M
↓ 2.21%
Q1 FY23Q/Q Change
Total Assets
583.1M
↓ 0.4%
Total Liabilities
128.3M
↓ 0.34%
Q2 FY23Q/Q Change
Total Assets
594.2M
↑ 1.9%
Total Liabilities
131.7M
↑ 2.72%
Q3 FY23Q/Q Change
Total Assets
600.3M
↑ 1.03%
Total Liabilities
137.4M
↑ 4.32%
FY17Y/Y Change
Operating Cash Flow
-8.9M
↓ 40.84%
Investing Cash Flow
3.8M
↓ 131.14%
Financing Cash Flow
2.8M
↓ 90.03%
FY18Y/Y Change
Operating Cash Flow
-4.2M
↓ 53.37%
Investing Cash Flow
-85.4M
↓ 2370.78%
Financing Cash Flow
100.2M
↑ 3529.57%
FY19Y/Y Change
Operating Cash Flow
-15.8M
↑ 279.07%
Investing Cash Flow
-2.1M
↓ 97.49%
Financing Cash Flow
14.4M
↓ 85.65%
FY20Y/Y Change
Operating Cash Flow
-19.9M
↑ 25.67%
Investing Cash Flow
-156.2M
↑ 7175.17%
Financing Cash Flow
189.4M
↑ 1217.69%
FY21Y/Y Change
Operating Cash Flow
-13.8M
↓ 30.65%
Investing Cash Flow
23.5M
↓ 115.05%
Financing Cash Flow
-7.6M
↓ 104.04%
FY22Y/Y Change
Operating Cash Flow
-22.1M
↑ 60.67%
Investing Cash Flow
44.0M
↑ 87.23%
Financing Cash Flow
-7.1M
↓ 7.63%
Q1 FY22Q/Q Change
Operating Cash Flow
-24.6M
↓ 8283.39%
Investing Cash Flow
19.7M
↑ 1731.2%
Financing Cash Flow
-10.5M
↓ 518.71%
Q2 FY22Q/Q Change
Operating Cash Flow
4.2M
↓ 117.17%
Investing Cash Flow
20.5M
↑ 4.05%
Financing Cash Flow
1.9M
↓ 117.73%
Q3 FY22Q/Q Change
Operating Cash Flow
-1.8M
↓ 142.18%
Investing Cash Flow
-3.2M
↓ 115.78%
Financing Cash Flow
-405.0K
↓ 121.76%
Q4 FY22Q/Q Change
Operating Cash Flow
46.0K
↓ 102.58%
Investing Cash Flow
7.0M
↓ 316.18%
Financing Cash Flow
2.0M
↓ 589.38%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.1M
↓ 8967.39%
Investing Cash Flow
28.8M
↑ 311.5%
Financing Cash Flow
-5.5M
↓ 378.36%
Q2 FY23Q/Q Change
Operating Cash Flow
3.0M
↓ 173.82%
Investing Cash Flow
-16.1M
↓ 155.81%
Financing Cash Flow
3.0M
↓ 154.27%

Technicals Summary

Sell

Neutral

Buy

Atricure Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Atricure Inc
Atricure Inc
-8.08%
-28.08%
-17.83%
-23.26%
8.14%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
11.64%
-1.96%
16.23%
21.48%
78.88%
Resmed Inc.
Resmed Inc.
4.59%
-27.5%
-26.08%
-23.07%
43.26%
Becton, Dickinson And Company
Becton, Dickinson And Company
-9.84%
-6.73%
-4.42%
-1.21%
-3.16%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
3.13%
-0.79%
46.16%
28.13%
216.56%
Alcon Ag
Alcon Ag
-2.54%
-9.1%
7.39%
12.91%
24.19%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Atricure Inc
Atricure Inc
34.48
NA
-1.18
-0.74
-0.05
-0.02
0.06
9.77
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
73.99
73.99
4.48
5.59
0.13
0.08
0.0
35.62
Resmed Inc.
Resmed Inc.
26.27
26.27
2.04
6.52
0.24
0.12
0.01
28.9
Becton, Dickinson And Company
Becton, Dickinson And Company
46.72
46.72
1.28
12.22
0.06
0.03
0.02
88.83
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
47.61
47.61
4.06
7.99
0.21
0.13
0.0
38.76
Alcon Ag
Alcon Ag
80.47
80.47
2.05
2.72
0.02
0.02
0.0
40.86
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Atricure Inc
Atricure Inc
Buy
$2.0B
8.14%
34.48
-6.52%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$111.0B
78.88%
73.99
22.14%
Resmed Inc.
Resmed Inc.
Buy
$23.8B
43.26%
26.27
20.72%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$69.2B
-3.16%
46.72
7.66%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$26.1B
216.56%
47.61
19.12%
Alcon Ag
Alcon Ag
Buy
$36.0B
24.19%
80.47
4.85%

Institutional Holdings

  • Vanguard Group Inc

    9.80%

  • BlackRock Inc

    8.26%

  • AllianceBernstein L.P.

    6.77%

  • Champlain Investment Partners, LLC

    3.82%

  • Fred Alger Management, LLC

    3.09%

  • First Light Asset Management, LLC

    3.08%

Company Information

atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.

Organization
Atricure Inc
Employees
1050
CEO
Mr. Michael H. Carrel
Industry
Health Technology

Discover More

FAQs